News

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Belite Bio completes its phase 3 trial for tinlarebant, a potential first treatment for Stargardt disease, with results expected in late 2025.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

We ask leading experts in the field what eye disease they would cure and why.

KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.

Viridian plans to submit a biologics license application (BLA) for VRDN-003 by year-end 2026.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.

Researchers conducted this study to determine how often and why spontaneous soft drusen regresses without atrophy in patients who had intermediate or atrophic age-related macular degeneration.

Optain Health secures $26 million in Series A funding to enhance AI-driven retinal disease detection and expand its technology.

Researchers will investigate a gene in the eye that is crucial for normal vision, but can cause retinal diseases when mutated that often lead to blindness.

Catch up on this week's highlights in retina.

A new study explores the "drusen ooze" hypothesis, revealing how drusen can regress without atrophy in age-related macular degeneration.

We ask leading experts in the field what eye disease they would cure and why.

Leading companies spotlight innovations in cataract and refractive surgery at the 43rd ESCRS Congress in Copenhagen

Immersive VR simulation helps patients better understand intraocular lens options.

Bausch + Lomb reveals promising results for the enVista Envy IOL, showcasing superior vision outcomes in cataract surgery patients.

Artificial intelligence is quickly expanding the breadth and depth of information clinicians can interpret, Prof Uy said

The virtual reality technology lets patients with cataract experience lens options in real-life scenarios, while a new strategic partnership aims to expand VR adoption.

At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow.

OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.